Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 10/20 | 1.00 |
| ▸ | PARP1 | P09874 | 6/20 | 1.00 |
| ▸ | TNKS2 | Q9H2K2 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 4/20 | 1.00 |
| ▸ | POLH | Q9Y253 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | FTO | Q9C0B1 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | IP6K2 | Q9UHH9 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 1.00 |
| ▸ | DHODH | Q02127 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 0.72 |
| ▸ | NPC1 | O15118 | 3/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29664745 | 1.00 | TNKS (1.00) | TNKSPARP1TNKS2KDM4ESMN1; SMN2 | |
| SCHEMBL311639 | 0.87 | TNKS (0.76) | TNKSPARP1TNKS2KDM4ESMN1; SMN2 | |
| SCHEMBL311918 | 0.87 | TNKS (0.76) | TNKSPARP1TNKS2KDM4ESMN1; SMN2 | |
| SCHEMBL1883775 | 0.86 | FTO (1.00) | TNKSPARP1TNKS2KDM4ESMN1; SMN2 | |
| SCHEMBL30000045 | 0.86 | FTO (1.00) | TNKSPARP1TNKS2KDM4ESMN1; SMN2 | |
| Flavone SCHEMBL27987776 | 0.86 | TNKS (0.84) | TNKSPARP1TNKS2KDM4ESMN1; SMN2 | |
| SCHEMBL31387550 | 0.85 | MAPT (0.74) | TNKSPARP1TNKS2KDM4ESMN1; SMN2 | |
| Luteolin SCHEMBL30913900 | 0.85 | POLH (0.75) | TNKSPARP1TNKS2KDM4ESMN1; SMN2 | |
| Luteolin SCHEMBL1229732 | 0.85 | POLH (0.75) | TNKSPARP1TNKS2KDM4ESMN1; SMN2 | |
| Luteolin SCHEMBL15271260 | 0.85 | POLH (0.75) | TNKSPARP1TNKS2KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118085410-A | Boron-based natural flavone brucite composite powder and preparation method and application thereof | 江西广源新材料有限公司 | 2024-05-28 | — | — | CN | claimed |
| US-20240122894-A1 | METHODS TO SYNTHESIZE FLAVONOID DIMERS AND OLIGOMERS AND THE USE THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2024-04-18 | — | — | US | claimed |
| EP-4259614-A1 | METHODS TO SYNTHESIZE FLAVONOID DIMERS AND OLIGOMERS AND THE USE THEREOF | National University of Singapore (SG) | 2023-10-18 | — | — | EP | claimed |
| CN-116829544-A | Synthesis method of flavonoid dimers and oligomers and application thereof | 新加坡国立大学 | 2023-09-29 | — | — | CN | claimed |
| US-20230119060-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE | MEDIENCE CO., LTD. (KR) | 2023-04-20 | — | — | US | claimed |
| US-20220249431-A1 | ANTIMYCOTIC | Karl-Franzens-Universität Graz (AT) | 2022-08-11 | — | — | US | claimed |
| WO-2022124994-A1 | METHODS TO SYNTHESIZE FLAVONOID DIMERS AND OLIGOMERS AND THE USE THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2022-06-16 | — | — | WO | claimed |
| EP-4003522-A1 | ANTIMYCOTIC | Karl-Franzens-Universität Graz (AT) | 2022-06-01 | — | — | EP | claimed |
| EP-3769815-A1 | ANTIMYCOTIC | Karl-Franzens-Universität Graz (AT) | 2021-01-27 | — | — | EP | claimed |
| US-20200123673-A1 | ELECTROLYTIC TIN ALLOY PLATING SOLUTION | C. UYEMURA & CO., LTD. (JP) | 2020-04-23 | — | — | US | claimed |
| US-20040229825-A1 | Pharmaceutical composition for treatment of infection with drug resistant bacterium and disinfectant | ALPS PHARMACEUTICAL IND., CO., LTD. (JP) | 2004-11-18 | — | — | US | claimed |
| EP-1438423-A1 | ENZYME ACTIVITY INDICATORS | Burton, Michael (GB) | 2004-07-21 | — | — | EP | claimed |
| EP-1435930-A2 | ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2004-07-14 | — | — | EP | claimed |
| WO-2003035900-A1 | ENZYME ACTIVITY INDICATORS | BURTON MICHAEL (GB) | 2003-05-01 | — | — | WO | claimed |
| WO-2003032969-A2 | ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2003-04-24 | — | — | WO | claimed |
| WO-2003026705-A1 | METHODS FOR STERILIZING BIOLOGICAL MATERIALS USING FLAVONOID/FLAVONOL STABILIZERS | CLEARANT, INC. (US) | 2003-04-03 | — | — | WO | claimed |
| US-20030059338-A1 | Methods for sterilizing biological materials using flavonoid/flavonol stabilizers | CLEARANT, INC. | 2003-03-27 | — | — | US | claimed |
| JP-2003504327-A | — | — | 2003-02-04 | — | — | JP | claimed |
| EP-1223928-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | Prendergast, Patrick Thomas (IE) | 2002-07-24 | — | — | EP | claimed |
| WO-2001003681-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | PRENDERGAST PATRICK T (IE) | 2001-01-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240122894-A1 | METHODS TO SYNTHESIZE FLAVONOID DIMERS AND OLIGOMERS AND THE USE THEREOF | ERG28, MGAM, CTRB2 | TNKS 3615/4885PARP1 3677/4885TNKS2 2755/4885 |
| US-20220249431-A1 | ANTIMYCOTIC | ETF1, FOXM1, RIF1 | TNKS 4403/4885PARP1 3190/4885TNKS2 4431/4885 |
| US-20230119060-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE | SLC5A2, SLC5A1, SLC5A6 | TNKS 4575/4885PARP1 4024/4885TNKS2 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.